Product Description
Atecegetran metoxil (more widely known as AZD0837), an anticoagulant and a prodrug, converted to a selective and reversible direct thrombin inhibitor (AR-H067637). Atecegetran metoxil participated in phase II clinical trials to prevent the stroke and systemic embolism in patients with non-valvular atrial fibrillation. (Sourced from: https://drugs.ncats.io/drug/4GU1D587JV)
Mechanisms of Action: FII Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Atrial Fibrillation|Stroke
Phase 2: Stroke|Atrial Fibrillation
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2007-001722-27 | P2 |
Suspended |
Atrial Fibrillation |
2012-12-05 |
|
| ASSURE-AF | P3 |
Terminated |
Atrial Fibrillation|Stroke |
2011-05-05 |
|
| D1250C00042 | P2 |
Completed |
Atrial Fibrillation |
2009-05-01 |
|
| D1250C00029 | P1 |
Completed |
Healthy Volunteers |
2009-03-01 |